-
公开(公告)号：US06872853B1
公开(公告)日：2005-03-29
申请号：US10111947
申请日：2000-10-23
申请人： Paul Adriaan Van Der Schaaf , Franz Schwarzenbach , Hans-Jörg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard , Regine Peter
发明人： Paul Adriaan Van Der Schaaf , Franz Schwarzenbach , Hans-Jörg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard , Regine Peter
IPC分类号： A61P3/04 , A61K31/135 , A61K31/137 , A61P15/10 , A61P25/22 , A61P25/24 , A61P25/30 , C07C209/84 , C07C211/42
CPC分类号： A61K31/137 , A61K31/135 , C07C211/42 , C07C2602/10
摘要： A cystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.
摘要翻译： 发现盐酸舍曲林的结晶形式，以下称为具有令人惊奇地增加药物吸收速率的溶出速率的多晶型CSC2。 此外，盐酸舍曲林盐酸盐溶剂合物的不同结晶形式，盐酸舍曲林盐酸盐水合物的结晶形式，以下称为多晶型CSC1，制备盐酸舍曲林无定形形式的方法，以及制备多晶型I， II，V和T1。
-
公开(公告)号：US06939992B2
公开(公告)日：2005-09-06
申请号：US10736195
申请日：2003-12-15
申请人： Paul Adriaan Van Der Schaaf , Franz Schwarzenbach , Hans-Jörg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
发明人： Paul Adriaan Van Der Schaaf , Franz Schwarzenbach , Hans-Jörg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
IPC分类号： A61P3/04 , A61K31/135 , A61K31/137 , A61P15/10 , A61P25/22 , A61P25/24 , A61P25/30 , C07C209/84 , C07C211/42 , C07C211/00
CPC分类号： A61K31/137 , A61K31/135 , C07C211/42 , C07C2602/10
摘要： A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug.Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.
摘要翻译： 发现盐酸舍曲林的结晶形式，以下称为具有令人惊奇地增加药物吸收速率的溶出速率的多晶型CSC2。 此外，盐酸舍曲林盐酸盐溶剂合物的不同结晶形式，盐酸舍曲林盐酸盐水合物的结晶形式，以下称为多晶型CSC1，制备盐酸舍曲林无定形形式的方法，以及制备多晶型I， II，V和T1。
-
公开(公告)号：US07442838B2
公开(公告)日：2008-10-28
申请号：US11101860
申请日：2005-04-08
申请人： Paul Adriaan Van Der Schaaf , Franz Schwarzenbach , Hans Jürg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
发明人： Paul Adriaan Van Der Schaaf , Franz Schwarzenbach , Hans Jürg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
IPC分类号： C07C211/42
CPC分类号： A61K31/137 , A61K31/135 , C07C211/42 , C07C2602/10
摘要： Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.
摘要翻译： 盐酸舍曲林多晶型II通过将氯化氢加入酮中的舍曲林游离胺溶液方便地制备。 在优选的方法中，在加入氯化氢之前加入接种有多晶型II和/或溶液的一些晶体的舍曲林游离胺溶液。
-
公开(公告)号：US06858643B2
公开(公告)日：2005-02-22
申请号：US10130043
申请日：2001-10-23
申请人： Paul Adriaan Van Der Schaaf , Heinz Wolleb , Annemarie Wolleb , Claudia Marcolli , Martin Szelagiewicz , Andreas Burkhard , Beat Freiermuth
发明人： Paul Adriaan Van Der Schaaf , Heinz Wolleb , Annemarie Wolleb , Claudia Marcolli , Martin Szelagiewicz , Andreas Burkhard , Beat Freiermuth
IPC分类号： A61K31/405 , A61P3/06 , A61P43/00 , C07D209/18 , C07D209/24 , A61K31/40 , C07D209/12
CPC分类号： C07D209/24
摘要： Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomers of fluvastatin, referred to as polymorphic Forms A, B1, B2, C, D and E, processes for the preparation of these crystalline forms and pharmaceutical compositions comprising them are disclosed.
摘要翻译： 称为氟伐他汀的（3R，5S） - 和（3S，5R） - 对映体的结晶形式，称为多晶型A，B1，B2，C，D和E，用于制备这些结晶形式和药物组合物 包括它们被公开。
-
公开(公告)号：US06696479B2
公开(公告)日：2004-02-24
申请号：US10208687
申请日：2002-07-30
申请人： Paul Adriaan Van Der Schaaf , Claudia Marcolli , Martin Szelagiewicz , Andreas Burkhard , Heinz Wolleb , Annemarie Wolleb
发明人： Paul Adriaan Van Der Schaaf , Claudia Marcolli , Martin Szelagiewicz , Andreas Burkhard , Heinz Wolleb , Annemarie Wolleb
IPC分类号： A61K31405
CPC分类号： C07D209/24 , Y10S514/951
摘要： Novel crystalline forms of Fluvastatin sodium hydrates were found, referred to hereinafter as polymorphic Forms C, D, E and F. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms, a process for the preparation of highly crystalline Fluvastatin sodium Form A, and pharmaceutical compositions comprising the crystalline forms.
摘要翻译： 发现氟伐他汀钠水合物的新型结晶形式，以下称为多晶型C，D，E和F.此外，本发明涉及制备这些结晶形式的方法，制备高度结晶氟伐他汀的方法 钠形式A和包含结晶形式的药物组合物。
-
公开(公告)号：US06906087B2
公开(公告)日：2005-06-14
申请号：US10130042
申请日：2001-10-23
IPC分类号： A61P25/24 , A61K31/137 , A61P43/00 , C07C213/08 , C07C213/10 , C07C217/74 , A61K31/135
CPC分类号： C07C213/10 , C07C217/74
摘要： Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
摘要翻译： 发现盐酸文拉法辛的结晶形式，以下称为多晶型A，B和D.此外，本发明涉及制备这些结晶形式的方法和包含结晶形式的药物组合物。
-
公开(公告)号：US07045661B2
公开(公告)日：2006-05-16
申请号：US11093484
申请日：2005-03-30
IPC分类号： C07C211/00
CPC分类号： C07C213/10 , C07C217/74
摘要： Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
-
公开(公告)号：US20050197404A1
公开(公告)日：2005-09-08
申请号：US11101860
申请日：2005-04-08
申请人： Paul Van Der Schaaf , Franz Schwarzenbach , Hans Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
发明人： Paul Van Der Schaaf , Franz Schwarzenbach , Hans Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
IPC分类号： A61K31/135 , A61K31/137 , C07C211/42
CPC分类号： A61K31/137 , A61K31/135 , C07C211/42 , C07C2602/10
摘要： Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.
摘要翻译： 盐酸舍曲林多晶型II通过将氯化氢加入酮中的舍曲林游离胺溶液方便地制备。 在优选的方法中，在加入氯化氢之前加入接种有多晶型II和/或溶液的一些晶体的舍曲林游离胺溶液。
-
公开(公告)号：US20050119351A1
公开(公告)日：2005-06-02
申请号：US10945786
申请日：2004-09-21
申请人： Paul Van Der Schaaf , Franz Schwarzenbach , Hans-Jorg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
发明人： Paul Van Der Schaaf , Franz Schwarzenbach , Hans-Jorg Kirner , Martin Szelagiewicz , Claudia Marcolli , Andreas Burkhard
IPC分类号： A61K31/135 , A61K31/137 , C07C211/42
CPC分类号： A61K31/135 , A61K31/137 , C07C211/42 , C07C2602/10
摘要： An improved process for the preparation of sertraline hydrochloride polymorphic form II is described, which process comprises seeding a solution of sertraline free amine in a ketone with some crystals of polymorphic form II and addition of hydrogen chloride, and wherein the solution is heated before addition of the hydrogen chloride. According to the present process, the metastable form II may be obtained in a reliable way with good yield and high purity with respect to other polymorphic forms as well as preparative residues such as educts or solvents.
摘要翻译： 描述了用于制备盐酸舍曲林多晶型II的改进方法，该方法包括将不饱和胺不饱和胺的溶液接种在具有多晶型II的一些晶体和加入氯化氢的酮中，并且其中将溶液加热 氯化氢。 根据本发明方法，可以以可靠的方式获得亚稳态II，相对于其它多晶形式以及制备残留物例如离析物或溶剂，其产率高，纯度高。
-
公开(公告)号：US20120101126A1
公开(公告)日：2012-04-26
申请号：US13280431
申请日：2011-10-25
IPC分类号： A61K31/47 , C07D215/14
CPC分类号： C07D215/14 , C07B2200/13
摘要： The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.
摘要翻译： 本发明涉及匹伐他汀半钙盐的新结晶形式，以下称为多晶型A，B，C，D，E和F，以及无定形形式。 此外，本发明涉及制备这些结晶形式的方法和包含这些结晶形式或无定形形式的无定形形式和药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.025 秒)
